Disclosure(s): No financial relationships to disclose
Disclosure(s):
Nathan Morrow, OD: No financial relationships to disclose
Keratoconus is a sight-threatening disease with a prevalence estimated to be as high as 1/400 people. For decades, the only treatment was surgical intervention with a penetrating keratoplasty. Corneal collagen crosslinking is FDA approved, minimally invasive, saves devastating vision loss, and avoids a trip to the operating room for transplantation. This course will review the science of corneal collagen crosslinking, studies supporting FDA-approval, when the procedure is indicated, the procedure itself, and expected outcomes.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Review the science of corneal collagen crosslinking
Identify when the procedure is indicated and the expected outcomes
